Acquired Company

Palvella Therapeutics completed the merger with Pieris Pharmaceuticals on December 13, 2024, and the combined company will operate under the name Palvella Therapeutics, Inc. with shares trading on Nasdaq under the ticker PVLA.

Pieris Pharmaceuticals Inc.is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Its pipeline includes inhalable Anticalin proteins to treat respiratory diseases and immuno-oncology multi-specifics tailored for the tumor microenvironment. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin® is a registered trademark of Pieris. Show more

255 State St Fl 9, Massachusetts, 02109-2615, US

www.pieris.com

Research and Development in Biotechnology

Professional, Scientific, and Technical Services

Start AI Chat

Market Cap

0.00

52 Wk Range

$N/A - $N/A

Previous Close

$16.13

Open

$15.01

Volume

51,728

Day Range

$13.26 - $15.35

Enterprise Value

0.00

Cash

0.00

Avg Qtr Burn

N/A

Insider Ownership

0.07%

Institutional Own.

52.92%

Qtr Updated

06/30/24

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
PRS-344/S095012 Details Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Cinrebafusp Alfa (PRS-343) (4-1BB/HER2 Bispecific) Details Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Elarekibep (PRS-060/AZD1402) Details Asthma, Lung disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PRS-220 (CTGF) Details Idiopathic pulmonary fibrosis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.